Scripps VIVO scripps research logo

  • Index
  • Log in
  • Home
  • People
  • Organizations
  • Research
  • Events
Search form

Temsirolimus combined with sorafenib in hepatocellular carcinoma: A phase I dose-finding trial with pharmacokinetic and biomarker correlates

Academic Article
uri icon
  • Overview
  • Research
  • Identity
  • Additional Document Info
  • View All
scroll to property group menus

Overview

authors

  • Kelley, R. K.
  • Nimeiri, H. S.
  • Munster, P. N.
  • Vergo, M. T.
  • Huang, Y.
  • Li, C. M.
  • Hwang, J.
  • Mulcahy, M. F.
  • Yeh, B. M.
  • Kuhn, Peter
  • Luttgen, M. S.
  • Grabowsky, J. A.
  • Stucky-Marshall, L.
  • Korn, W. M.
  • Ko, A. H.
  • Bergsland, E. K.
  • Benson, A. B.
  • Venook, A. P.

publication date

  • July 2013

journal

  • Annals of Oncology  Journal

subject areas

  • Aged
  • Antineoplastic Combined Chemotherapy Protocols
  • Biomarkers
  • Biomarkers, Tumor
  • Carcinoma, Hepatocellular
  • Disease-Free Survival
  • Drug Administration Schedule
  • Female
  • Humans
  • Liver Neoplasms
  • Male
  • Maximum Tolerated Dose
  • Middle Aged
  • Neoplastic Cells, Circulating
  • Niacinamide
  • Phenylurea Compounds
  • Protein Precursors
  • Prothrombin
  • Sirolimus
  • Treatment Outcome
  • alpha-Fetoproteins
scroll to property group menus

Research

keywords

  • hepatocellular carcinoma
  • mTOR
  • pharmacokinetics
  • sorafenib
  • temsirolimus
scroll to property group menus

Identity

PubMed Central ID

  • PMC3690907

International Standard Serial Number (ISSN)

  • 0923-7534

Digital Object Identifier (DOI)

  • 10.1093/annonc/mdt109

PubMed ID

  • 23519998
scroll to property group menus

Additional Document Info

start page

  • 1900

end page

  • 1907

volume

  • 24

issue

  • 7

©2021 The Scripps Research Institute | Terms of Use | Powered by VIVO

  • About
  • Contact Us
  • Support